bi 894416
Small moleculeexperimental
Clinical trial activity
7 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
7
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Nov 2, 2017 (NCT03315936)
Timeline
2010s
- Jan 1, 2017
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Tyrosine-protein kinase SYKINHIBITOR
SYK inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04540874 | Phase 1 | Oct 5, 2020 | Boehringer Ingelheim |
| NCT04232839 | Phase 1 | Feb 20, 2020 | Boehringer Ingelheim |
| NCT04060719 | Phase 1 | Sep 4, 2019 | Boehringer Ingelheim |
| NCT03971539 | Phase 1 | Jul 11, 2019 | Boehringer Ingelheim |
| NCT03871595 | Phase 1 | Mar 20, 2019 | Boehringer Ingelheim |
| NCT03722173 | Phase 1 | Nov 13, 2018 | Boehringer Ingelheim |
| NCT03315936 | Phase 1 | Nov 2, 2017 | Boehringer Ingelheim |
Showing 7 of 7 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Boehringer Ingelheim | For profit | 7 | 7 | 1 | 2017 |
1 organizations
Page 1 / 1